| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective.
|
2020
|
2.01
|
|
2
|
AIOM chooses ESMO Open-Cancer Horizons as its official journal: a warm welcome from ESMO Open.
|
2016
|
1.40
|
|
3
|
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort.
|
2017
|
1.40
|
|
4
|
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer.
|
2017
|
1.39
|
|
5
|
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients.
|
2017
|
1.38
|
|
6
|
Cancer and liver cirrhosis: implications on prognosis and management.
|
2016
|
0.91
|
|
7
|
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls.
|
2016
|
0.88
|
|
8
|
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.
|
2016
|
0.87
|
|
9
|
Clinical value of early detection of circulating tumour DNA-BRAF(V600mut) in patients with metastatic melanoma treated with a BRAF inhibitor.
|
2017
|
0.86
|
|
10
|
Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer.
|
2016
|
0.84
|
|
11
|
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence.
|
2016
|
0.81
|
|
12
|
Mechanisms of resistance to EGFR-targeted drugs: lung cancer.
|
2016
|
0.81
|
|
13
|
Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors.
|
2016
|
0.81
|
|
14
|
Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers.
|
2016
|
0.81
|
|
15
|
Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology.
|
2016
|
0.80
|
|
16
|
Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.
|
2016
|
0.79
|
|
17
|
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.
|
2016
|
0.79
|
|
18
|
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.
|
2016
|
0.78
|
|
19
|
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.
|
2016
|
0.78
|
|
20
|
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer.
|
2016
|
0.78
|
|
21
|
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options.
|
2016
|
0.77
|
|
22
|
Radiological staging in pregnant patients with cancer.
|
2016
|
0.77
|
|
23
|
Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
|
2016
|
0.77
|
|
24
|
Renal insufficiency and cancer treatments.
|
2016
|
0.77
|
|
25
|
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.
|
2017
|
0.77
|
|
26
|
Recent advances in the biology of human circulating tumour cells and metastasis.
|
2016
|
0.77
|
|
27
|
Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma.
|
2016
|
0.77
|
|
28
|
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer.
|
2017
|
0.76
|
|
29
|
Cancer immune cycle: a video introduction to the interaction between cancer and the immune system.
|
2016
|
0.76
|
|
30
|
Recent developments and translational aspects in targeted therapy for metastatic breast cancer.
|
2016
|
0.76
|
|
31
|
Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study.
|
2016
|
0.75
|
|
32
|
Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example.
|
2016
|
0.75
|
|
33
|
Molecular pathology of cancer: how to communicate with disease.
|
2016
|
0.75
|
|
34
|
Twenty years of anti-HER2 therapy-associated cardiotoxicity.
|
2016
|
0.75
|
|
35
|
Critically ill patients with cancer: chances and limitations of intensive care medicine-a narrative review.
|
2016
|
0.75
|
|
36
|
Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort.
|
2016
|
0.75
|
|
37
|
Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant.
|
2016
|
0.75
|
|
38
|
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.
|
2016
|
0.75
|
|
39
|
Interventions to improve care coordination between primary healthcare and oncology care providers: a systematic review.
|
2016
|
0.75
|
|
40
|
In the literature: May 2016.
|
2016
|
0.75
|
|
41
|
Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology.
|
2016
|
0.75
|
|
42
|
TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib.
|
2016
|
0.75
|
|
43
|
Cancer in pregnancy: disentangling treatment modalities.
|
2016
|
0.75
|
|
44
|
Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial.
|
2016
|
0.75
|
|
45
|
Novel prognostic prediction models for patients with stage IV colorectal cancer after concurrent curative resection.
|
2016
|
0.75
|
|
46
|
Threat posed by unproven drugs in medical oncology.
|
2016
|
0.75
|
|
47
|
Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015.
|
2016
|
0.75
|
|
48
|
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis.
|
2016
|
0.75
|
|
49
|
Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis.
|
2016
|
0.75
|
|
50
|
The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe.
|
2016
|
0.75
|